Department of Urology, Erzurum Regional Training and Research Hospital, University of Health Sciences, Erzurum, Turkey.
Department of Infectious Diseases and Clinical Microbiology, Erzurum Regional Training and Research Hospital, University of Health Sciences, Erzurum, Turkey.
Andrology. 2022 Jan;10(1):24-33. doi: 10.1111/andr.13081. Epub 2021 Aug 2.
A potential role of testosterone among sex hormones has been hypothesized in identifying sex-related differences in the clinical consequences of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Due to the high global prevalence of hypogonadism, the relationship between hypogonadism and SARS-CoV-2 infection outcomes deserves an in-depth study.
The present study aimed to investigate the relationship of serum testosterone with other laboratory parameters on the prognosis of coronavirus disease-19 (COVID-19) in male patients with COVID-19 diagnosis.
This prospective cohort study included 358 male patients diagnosed with COVID-19 and 92 COVID-19 negative patients admitted to the urology outpatient clinics as a control group. The COVID-19 patients were divided into groups according to prognosis (mild-moderate and severe group), lung involvement in chest computed tomography (<50% and >50%), intensive care unit needs, and survival.
The measured serum total testosterone level of the COVID-19 patients group was found to be significantly lower than that of the control group (median, 140 ng/dl; range, 0.21-328, 322 ng/dl; range, median, 125-674, p < 0.001, respectively). The serum TT levels were statistically significantly lower in severe COVID-19 patients compared to mild-moderate COVID-19 patients (median, 85.1 ng/dl; range, 0.21-532, median, 315 ng/dl; range, 0.88-486, p < 0.001, respectively), in COVID-19 patients in need of intensive care compared to COVID-19 patients who did not need intensive care (median, 64.0 ng/dl; range, 0.21-337, median, 286 ng/dl; range, 0.88-532 p < 0.001, respectively), and in COVID-19 patients who died compared to survivors (median, 82.9 ng/dl; range, 2.63-165, median, 166 ng/dl; range, 0.21-532, p < 0.001, respectively).
Our data are compatible with low TT levels playing a role on the pathogenesis of the disease in Covid-19 patients with poor prognosis and a mortal course and may guide clinicians in determining the clinical course of the disease.
雄激素作为一种潜在的性激素，其在严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的临床后果方面的性别差异中具有一定作用。由于全球范围内低促性腺激素血症的高发，低促性腺激素血症与 SARS-CoV-2 感染结局之间的关系值得深入研究。
本研究旨在探讨血清睾酮与其他实验室参数与男性 COVID-19 患者 COVID-19 预后的关系。
本前瞻性队列研究纳入了 358 名男性 COVID-19 患者和 92 名 COVID-19 阴性患者作为对照组，这些患者均在泌尿外科门诊就诊。根据预后（轻中度和重度组）、胸部计算机断层扫描（CT）中肺受累程度（<50%和>50%）、需要重症监护和生存情况对 COVID-19 患者进行分组。
COVID-19 患者组的血清总睾酮水平明显低于对照组（中位数为 140ng/dl；范围为 0.21-328ng/dl；中位数为 125-674ng/dl；范围为 0.21-328ng/dl；p<0.001）。与轻中度 COVID-19 患者相比，重度 COVID-19 患者的血清 TT 水平明显更低（中位数为 85.1ng/dl；范围为 0.21-532ng/dl；中位数为 315ng/dl；范围为 0.88-486ng/dl；p<0.001），需要重症监护的 COVID-19 患者的血清 TT 水平明显低于不需要重症监护的 COVID-19 患者（中位数为 64.0ng/dl；范围为 0.21-337ng/dl；中位数为 286ng/dl；范围为 0.88-532ng/dl；p<0.001），死亡 COVID-19 患者的血清 TT 水平明显低于幸存者（中位数为 82.9ng/dl；范围为 2.63-165ng/dl；中位数为 166ng/dl；范围为 0.21-532ng/dl；p<0.001）。
本研究数据表明，低 TT 水平可能在 COVID-19 患者的发病机制中起作用，这些患者预后不良且病死率高，这可能为临床医生判断疾病的临床过程提供指导。
